Alan R. Olzinski

1.3k total citations
19 papers, 680 citations indexed

About

Alan R. Olzinski is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan R. Olzinski has authored 19 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan R. Olzinski's work include Nitric Oxide and Endothelin Effects (3 papers), Cardiovascular Function and Risk Factors (3 papers) and Atherosclerosis and Cardiovascular Diseases (3 papers). Alan R. Olzinski is often cited by papers focused on Nitric Oxide and Endothelin Effects (3 papers), Cardiovascular Function and Risk Factors (3 papers) and Atherosclerosis and Cardiovascular Diseases (3 papers). Alan R. Olzinski collaborates with scholars based in United States, United Kingdom and Canada. Alan R. Olzinski's co-authors include Robert N. Willette, Beat M. Jucker, Karpagam Aravindhan, Rosanna C. Mirabile, David J. Behm, Roberta E. Bernard, Marianne Eybye, Stephen C. Lenhard, Tom C. Hu and Gregory Turner and has published in prestigious journals such as Arteriosclerosis Thrombosis and Vascular Biology, Journal of Pharmacology and Experimental Therapeutics and Cardiovascular Research.

In The Last Decade

Alan R. Olzinski

18 papers receiving 669 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan R. Olzinski United States	15	238	168	148	126	115	19	680
Ruqiong Nie China	16	228 1.0×	104 0.6×	201 1.4×	128 1.0×	92 0.8×	56	665
Johanna M. U. Silvola Finland	15	312 1.3×	147 0.9×	177 1.2×	151 1.2×	86 0.7×	22	707
Karpagam Aravindhan United States	10	248 1.0×	143 0.9×	196 1.3×	184 1.5×	69 0.6×	11	666
Rodica Niculescu United States	13	142 0.6×	127 0.8×	180 1.2×	216 1.7×	102 0.9×	20	585
Yunpeng Shang China	13	321 1.3×	297 1.8×	214 1.4×	156 1.2×	58 0.5×	31	763
Suvi E. Heinonen Finland	12	221 0.9×	53 0.3×	110 0.7×	162 1.3×	153 1.3×	24	559
Mette L. Johansen United States	12	195 0.8×	92 0.5×	106 0.7×	78 0.6×	195 1.7×	18	671
Eto Y Japan	14	436 1.8×	73 0.4×	176 1.2×	152 1.2×	64 0.6×	28	795
Bingqing Deng China	15	306 1.3×	79 0.5×	156 1.1×	91 0.7×	57 0.5×	42	642
Aigul Moldobaeva United States	16	260 1.1×	181 1.1×	74 0.5×	63 0.5×	120 1.0×	29	614

Countries citing papers authored by Alan R. Olzinski

Since Specialization

Citations

This map shows the geographic impact of Alan R. Olzinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan R. Olzinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan R. Olzinski more than expected).

Fields of papers citing papers by Alan R. Olzinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan R. Olzinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan R. Olzinski. The network helps show where Alan R. Olzinski may publish in the future.

Co-authorship network of co-authors of Alan R. Olzinski

This figure shows the co-authorship network connecting the top 25 collaborators of Alan R. Olzinski. A scholar is included among the top collaborators of Alan R. Olzinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan R. Olzinski. Alan R. Olzinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Olzinski, Alan R., Larry J. Jolivette, Timothy W. Sikorski, et al.. (2023). Development of an LC–MS/MS Assay for Quantification of intact INSL3 in Rat Plasma. Bioanalysis. 15(19). 1169–1178.

Gobbetti, Thomas, et al.. (2021). A Structured Approach to Optimizing Animal Model Selection for Human Translation: The Animal Model Quality Assessment. ILAR Journal. 62(1-2). 66–76. 16 indexed citations

Morgan, Lisa, Alan R. Olzinski, John J. Upson, et al.. (2012). Soluble Epoxide Hydrolase Inhibition Does Not Prevent Cardiac Remodeling and Dysfunction After Aortic Constriction in Rats and Mice. Journal of Cardiovascular Pharmacology. 61(4). 291–301. 22 indexed citations

Bao, Weike, Pu Qin, Saul Needle, et al.. (2010). Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat. Journal of Cardiovascular Pharmacology. 56(2). 147–155. 88 indexed citations

Willette, Robert N., Marianne Eybye, Alan R. Olzinski, et al.. (2009). Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease. Journal of Pharmacology and Experimental Therapeutics. 330(3). 964–970. 37 indexed citations

Turner, Gregory, Alan R. Olzinski, Roberta E. Bernard, et al.. (2009). Assessment of macrophage infiltration in a Murine model of abdominal aortic aneurysm. Journal of Magnetic Resonance Imaging. 30(2). 455–460. 44 indexed citations

Olzinski, Alan R., Gregory Turner, Roberta E. Bernard, et al.. (2009). Pharmacological Inhibition of C-C Chemokine Receptor 2 Decreases Macrophage Infiltration in the Aortic Root of the Human C-C Chemokine Receptor 2/Apolipoprotein E ^−/− Mouse: Magnetic Resonance Imaging Assessment. Arteriosclerosis Thrombosis and Vascular Biology. 30(2). 253–259. 36 indexed citations

Turner, Gregory, Alan R. Olzinski, Roberta E. Bernard, et al.. (2008). In Vivo Serial Assessment of Aortic Aneurysm Formation in Apolipoprotein E–Deficient Mice via MRI. Circulation Cardiovascular Imaging. 1(3). 220–226. 40 indexed citations

Olzinski, Alan R., et al.. (2008). Patterns of USPIO Deposition in Murine Atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology. 28(9). 1 indexed citations

10.

Jucker, Beat M., Christopher Doe, Christine G. Schnackenberg, et al.. (2007). PPARδ Activation Normalizes Cardiac Substrate Metabolism and Reduces Right Ventricular Hypertrophy in Congestive Heart Failure. Journal of Cardiovascular Pharmacology. 50(1). 25–34. 31 indexed citations

11.

Nerurkar, Sandhya S., Alan R. Olzinski, Kendall S. Frazier, et al.. (2007). p38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomarkers. 12(1). 87–112. 12 indexed citations

12.

Jucker, Beat M., Dewen Yang, Warren Casey, et al.. (2007). Selective PPARδ agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study. American Journal of Physiology-Endocrinology and Metabolism. 293(5). E1256–E1264. 22 indexed citations

13.

Olzinski, Alan R., Roberta E. Bernard, Karpagam Aravindhan, et al.. (2007). p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology. 28(2). 265–271. 79 indexed citations

14.

Johns, Douglas G., Zhaohui Ao, Marianne Eybye, et al.. (2005). Rosiglitazone Protects against Ischemia/Reperfusion-Induced Leukocyte Adhesion in the Zucker Diabetic Fatty Rat. Journal of Pharmacology and Experimental Therapeutics. 315(3). 1020–1027. 19 indexed citations

15.

Olzinski, Alan R., Shui‐Ping Zhao, David J. Behm, et al.. (2005). Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovascular Research. 66(1). 170–178. 40 indexed citations

16.

Olzinski, Alan R., Tom C. Hu, Stephen C. Lenhard, et al.. (2005). Differential uptake of ferumoxtran‐10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: Critical determinants of atherosclerotic plaque labeling. Journal of Magnetic Resonance Imaging. 21(4). 432–442. 87 indexed citations

17.

Ju, Haisong, David J. Behm, Marianne Eybye, et al.. (2003). p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension. Journal of Pharmacology and Experimental Therapeutics. 307(3). 932–938. 54 indexed citations

18.

Nerurkar, Sandhya S., Charles F. Sauermelch, Alan R. Olzinski, et al.. (2002). Sustained Activation of p38 Mitogen-Activated Protein Kinase Contributes to the Vascular Response to Injury. Journal of Pharmacology and Experimental Therapeutics. 301(1). 15–20. 43 indexed citations

19.

Willette, Robert N., Karen M. Anderson, Allen H. Nelson, et al.. (2001). Enrasentan Improves Survival, Limits Left Ventricular Remodeling, and Preserves Myocardial Performance in Hypertensive Cardiac Hypertrophy and Dysfunction. Journal of Cardiovascular Pharmacology. 38(4). 606–617. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact